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HF with defined LVEF, follow-up data (mean 692 days) were obtained on
798 patients with HF and or LVEF s 45% enrollad in the SOLVD Registry
Substudy. Patients were divided into two groups based on gender.
Mortalityby EFGroupandGsnder
EF> 45% Males (n= 156) Femalee (n = 66)
Death 12 (7.7%) 10(14.7%) NS
EF s 45% Malee (n =461) Females (n= 113)
Death 104 (22.6”/0) 22 (19.5%) NS
Conclusion: In patienta with HF and either presemd or impaired LV
systolic function, gender is not an independent predictor of mortality.
1977-1751Qualityof Life Asse~~mentinAdvan~ed
Congestive Heart Faiiure Patients on intermittent
inotropic infusion Program
S. Sehgal, L. Heaney, A. Mariua, R. Femandez, W.A. Clark, E.N. Silber,
P.Denes. Cardiovascular Institute, Michael Reese Hospita/and Medica/
Carrtec Chicago, IL, USA
This study wasperformad toassessthe Quality of Life (QOL) benefits of inter-
mittent inotropic(mikinone anddobutamine) infusion program inpatients (pts)
with class IIMV congestive heart failure. Methods: The heart failure program
included pt assessments, intravenous inotropic infusions, optimization of oral
medications, comprehensive education concerning weight, fluid intake and
diet. Benefits were determined through a self-administered questionnaire.
The Minneeota Living With Heart Failure (LHF) questionnaire consisting of
21 questions, scored in a scale of Oto 5 in ascendingorder of impairment,
was uaed to assess the QOL, physical and psychosocial abilities. Results:
Data was complied from 916 questionnaires administered to 90 pts (46 M &
44 F; age 64 + 13.3 yra) with a mean follow-up of 287 days. At enrollment
the NYHAclaae Ill pts (n = 37) had a better baseline mean score than NYHA
class IV (n = 53) pts (2.5 * 0.9 vs 3.6 + 0.4p c 0.001). In the first 6 months
of infuaion therapy 56% improvement in LHF mean ecorea (3.1 * 1.0 vs 1.8
+ 1.3; p < 0.001) was seen, thereafter maintaining a sustained effect. The
physical and emotional dimension scores of the questionnaire showed a aim-
ilar trend at the end of 6 montha (p < 0.001), and the number of respondants
to overall feeling ‘very much impaired’ decreased from 47?/.to 9%. The pta
who died had a worse baseline LHF score than surviving pts (3.7 +0.3 VS2.8
+0.9; p < 0.05). In those ptawhodiadthetokd and physical mean scoresdid
not change significantly from baseline as COmParadto survivom (P < 0.001)..
The 1 yr ali-oauae mortality was 19Y0.Conclusions: 1) The infusion program
significantly improves the QOL measures including phyaical and emotional
dimensions in advanced heari failure. 2). No adverse effect on mortality was
seen. 3) Failure in improvement of LHF scores auggeats adverse clinical
outcome.
D977176 No Ethioiogic Differences in Survivai Benefitefrom Amiodarone in Severe Congestive Heart
Faiiure
D.R. Nul, H.O. Grancelli, S.D. Varini, S. Soifer, O. Scapin, S. Perrone,
G.R. Bortman, H.C. Doval. GESICA trial, GEMA, Buenos Aires, Argentina
Trials with amiodarone in congestive heart failure, have produce discordant
results with regard to effects on survival. A mortality reduction benefit trend
was reported only in non-isquemic patients in CHF-STATtrial while GESICA
trial reported an overall 28Y0 mortality reduction.
Gesioa mortality reduction is analyzed in relation to etiology.
A total population of 516 pts with aevere CHF were included (NYHA II
advanced 106 pts, Ill 249 pte, IV 159 pts, and mean ejection fraction 19
+ 7%). Iaehemic etiology was established in 200 pts (38.8%) mnsidering
Q wave preaence and myoeardial infarction history, and non-lachemic in
316 pts (61.2%). Among non-ischemic patients, Idiopathic cardiomyopathy
waa established in 107 pts (20.7%) considering the absence of any other
ethnologicfactors. Two yeara actuarial mortality was considered and Log rank
test was used for statistical analyses.
Two-years actuarialmortality
Etiology Control Amiodarone RR 95% c1 P
Ischemic 59.7% 42.9Y0 0.62 0.40-0.96 0.03
Non-isohsmlc 53.2% 43.7”k 0.77 0.54-1.09 0.07
Idlopathk 61.1% 3s.5% 0.57 0.31-1.07 0.07
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1977-1771 Teiemanagementof Congestive Heart Faiiure:
Raauita of Daiiy Weight and Symptom Tracking
R.E. Williams, L. Keiler, M. Sprang, C. Mehan. Northwestern Universi~
Evanston Hospital, Evanston, IL, USA
Optimal clinical management of heari failure (HF) requires monitoring of
weight changes and symptoma of congestion in order to prevent exacerba-
tions due to fluid accumulation. An emerging approach to such monitoring,
known as ‘telemanagement,’ applies telephone technology to interactions
with and management of patient care, We hypothesized that patient initi-
ated daily self-reporting of weighte and symptoms could be accomplished
consistently, by applying daily telemanagement. Further, we hypothesized
that this approach would predict diaeaae progression, allowing intervention
prior to symptomatic deterioration, with the goal of preventing unnecesaaty
hospitalizations. Forty-twoconsecutive outpatient with NYHAclaes II-IV HF
from our HF clinic were followed fora mean of 116+ 10 days. Patients were
instructed to call daily to a central reporting number between the hours of 6
am and 11am, using a touch-tone phone. Callers were asked to report their
morning weight, and “yes” or “no” answera to a HF symptom questionnaire,
indicating if a change in symptoms had occurred since last reporting. All ra-
sponsas were monitored by a HF trainad nurse, who identified alterations in
weight or symptom acores, and triagad care. Of the 42 patienta, 3 were with-
drawn baeauee of transition to hospice care, while 2 died of sudden death.
Of the remaining 37 patients, none withdrew during the reporting period.
The overall compliance rate for daily reporting was 66%, as determined by
the percent of daily expected calls which were actually received. The rate of
compliance was leas (76% vs. 90Yo)for weekend call-ins, compared to week-
days. Overall, increases in weight tended to ba associated with additional
reporting of mngestion-relatad symptoms. However, increased congestion
symptoms did not appear to track weight gains aa consistently for individ-
ual patients. Intewention for early weight gain with directed adjustments in
HF medications and reinforcement of diet appeared to reduce the need for
hospitalization, to an average of 0.74 per patient per year. These results
indicate that patients are highly compliant with daily weight and symptom
reporting over a significant period of time. In addition, early fluid accumula-
tion, as indicated by an increase in daily weight, precedes development of
significant HF symptoms in most patients. Finally, through early intervention
(medication and diet), daily telemanagement is able to reduce the need for
hospitalizations for hearl failure.
1977-178\ Different Predictors insuddenOrPrOgreasive’
Heart Failure Death in Severe Heart Faiiure
S. Soifer, DR. Nul, HO. Grancelli, S.D. Varini, O. Scapin, S. Perrone,
N. Prieto, H.C. Doval. GESICA trial, GEMA, Buenos Aires, Argentina
As a secondary point of GESICA trial (Randomised trial of Iow-doee amio-
darone in severe congestive heart failure) we evaluated the prognostic sig-
nificance of M clinical variables on admisaion in 516 pts with severe heart
failure (NYHA II advanced 106 pts, Ill 249 pts, IV 159 pts, and mean ejection
fraction 19 + 7%), in relation to total mortality and the death mode involved
(audden or progressive heart failure death). End point was total mortality.
Two yeara actuarial mortality was 46% (193/516). Death was recorded as
due to progressive heart failure 96 p (50%), sudden death 71 p (37%) (death
within an hour of presentation of new symptoms), unknown 18 p (9%), and
non-cardiac death 8 p (4%). All deaths were classified blindly by an event
committee. A correction adjustment was done by the proportional-hazards
Cox model. The highest relative risk (RR) for total mortality was Functional
Capacity (FC) RR 1.74 (p> 0.0001), followed by Non-Sustained Ventricular
Tachyeardia (NSVT) in the admisaion helter, RR 1.61 (p < 0.001), Serum
Urea (SU) mg/dl RR 1.01 (p < 0.002), Ejection Fraction (EF) RR 1.41 (p <
0.01), and amiodarone therapy RR 0.68 (p < 0.01).
Different independent predictors were found for sudden death: NSVT RR
2.59 (p c 0.0001); EF RR 1.30 (p < 0.01) and for progressive heart failure
death: FC RR 1.90 (p < 0.0001), SU RR 1.015 (p < 0.001); systolic bled
pressure RR 0.98 (p < 0.01).
Conclusions: independent predictors of total mortality in patients with se-
vere heart failure proved to be different for sudden death and for progressive
heart failure death.
Conclusions: Amiodarone mortality reduction observed in GESICA trial
was not related to etiology. A similar mortality reduction was observed in
ischemicand non-ischemic defined patients, andalaoconsidering a subgroup
with idiopathic cardiomyopathy.
